The progression-free survival ( PFS ) of the study group and the control group was 4.0 months ( 95 % CI : 3.1-4 .9 ) and 3.0 months ( 95 % CI : 2.4-3 .6 ) respectively , the difference being statistically significant ( ( 2 ) = 4.750 , P = 0.029 ) .